STOCK TITAN

NeuroSense Therapeutics Ltd - NRSN STOCK NEWS

Welcome to our dedicated news page for NeuroSense Therapeutics (Ticker: NRSN), a resource for investors and traders seeking the latest updates and insights on NeuroSense Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NeuroSense Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NeuroSense Therapeutics's position in the market.

Rhea-AI Summary
NeuroSense's PrimeC shows significant increase in survival rate of induced motor neurons in ALS study, reinforcing previous findings. PrimeC performed among the best in improving motor neuron survival compared to other ALS drugs. Clinical topline results from Phase 2b study expected in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.91%
Tags
none
-
Rhea-AI Summary
NeuroSense terminates equity offering program, fully funded into Q2 2024; ALS Phase 2b trial data expected Q4 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
-
Rhea-AI Summary
NeuroSense opens EU office and receives SME status from EMA, offering regulatory guidance and engagement. Plans to enroll patients in Phase 3 ALS study. Clinical results from Phase 2b study expected end of 2023. Commences global Phase 3 study in 2024 with numerous European sites. Financial benefits include fee reductions and exemptions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
none
Rhea-AI Summary
NeuroSense receives key patent for ALS treatment drug combination
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
none
-
Rhea-AI Summary
NeuroSense to present PARADIGM Phase 2b ALS study at conferences, expects to report topline results in Q4 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
conferences
-
Rhea-AI Summary
NeuroSense Therapeutics will host an investor webinar conference on September 12, 2023, to discuss its scientific advances, clinical trials, and upcoming catalysts. The company is in a strong financial position with a capital runway beyond the expected data readout in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
conferences
Rhea-AI Summary
NeuroSense Therapeutics completed patient enrollment for its Phase 2b ALS study and expects topline results in Q4 2023. The company raised $4.5 million in capital, providing funding until Q2 2024. NeuroSense also announced a strategic scientific agreement with Biogen and is preparing for a Phase 2 AD trial and exploring co-development for PD indication.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.21%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
conferences
-
Rhea-AI Summary
NeuroSense Therapeutics announced its participation in two upcoming conferences focused on advancing treatments for amyotrophic lateral sclerosis (ALS). The company aims to create new partnerships and strengthen existing connections with the ALS scientific community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.42%
Tags
conferences
News
Rhea-AI Summary
NeuroSense Therapeutics provided an update on its clinical and operational developments in Q2 2023. The Phase 2b ALS PARADIGM trial completed patient enrollment, with topline results expected in Q4 2023. 96% of participants chose to continue in the study. NeuroSense also announced a strategic scientific agreement with Biogen to evaluate the impact of PrimeC on neurofilament levels in ALS patients. In preparation for the Phase 2 AD trial, a biomarker study revealed elevated levels of TDP-43 in AD patients. NeuroSense completed a biomarker study in PD patients, observing a significant decrease in AGO2 levels. The company raised $4.5 million in capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
NeuroSense Therapeutics Ltd

Nasdaq:NRSN

NRSN Rankings

NRSN Stock Data

24.96M
10.65M
28.05%
0.91%
0.41%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Israel
Herzliya

About NRSN

advancing research, development and therapy for als. neurosense therapeutics is a biotech company focusing on the development of mirnas as a novel treatment for als. currently preparing for a first clinical study in patients in usa